Khaled Musallam/LinkedIn
Aug 13, 2026, 11:05
Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Hematology, adding:
“Pleased to share our latest ‘2026 Update on Clinical Trials in β-Thalassemia,’ published today in the American Journal of Hematology.
It is incredibly fulfilling to reflect on how much the field has advanced since our last update in 2021 with new approvals and an expanding pipeline continuing to reshape the treatment landscape for β-thalassemia.”
Title: 2026 Update on Clinical Trials in β-Thalassemia
Authors: Khaled M. Musallam, Franco Locatelli, Mattia Algeri, Maria Domenica Cappellini, Ali T. Taher

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer
-
Nov 8, 2026, 05:24Recognising Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding – RPTH Journal
-
Nov 8, 2026, 05:11WFH CCS 2027 Abstract Submission Now Open – World Federation of Hemophilia